Literature DB >> 23320495

Inactivation of Plasmodium spp. in plasma and platelet concentrates using riboflavin and ultraviolet light.

Shawn D Keil1, Patti Kiser, James J Sullivan, Amy S Kong, Heather L Reddy, Anne Avery, Raymond P Goodrich.   

Abstract

BACKGROUND: Photochemical treatment of blood products could help prevent transfusion-transmitted malaria and reduce the need for donor deferrals. In this study we evaluated the effectiveness of riboflavin and ultraviolet (UV) light against both Plasmodium falciparum, which causes the most severe form of human malaria, and Plasmodium yoelii, an in vivo murine model for malaria. STUDY DESIGN AND METHODS: Plasma and platelet (PLT) concentrates were inoculated with either P. falciparum- or P. yoelii-infected red blood cells (RBCs). Aliquots from each unit were collected after inoculation, after addition of riboflavin, and after treatment. In vitro P. falciparum growth was assessed using thin blood films of duplicate samples at 24, 48, 72, and 96 hours. P. yoelii parasitemia was followed in mice for 14 days postinoculation.
RESULTS: In the in vitro studies, the mean P. falciparum parasitemia increased 12- to 19-fold in pretreatment samples, both before and after addition of riboflavin, after 96-hour culture. Few parasites were observed in Mirasol-treated units at 24 hours; those that were observed were degenerating. Through the remainder of the 96-hour culture period, cultures of treated samples were negative. In the in vivo study, mouse plasma containing P. yoelii-infected RBCs had a mean starting titer of 4.6 log mouse infectious dose 50%/mL. No infectious parasite was detected in treated samples.
CONCLUSION: Treatment with riboflavin and UV light was effective at reducing viable P. falciparum in both PLT and plasma products by at least 3.2 logs. Additionally, an at least 4.4-log reduction was observed with P. yoelii.
© 2013 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23320495     DOI: 10.1111/trf.12079

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  10 in total

1.  Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro.

Authors:  Andrew P Cap; Heather F Pidcoke; Shawn D Keil; Hilary M Staples; Manu Anantpadma; Ricardo Carrion; Robert A Davey; Ashley Frazer-Abel; Audra L Taylor; Richard Gonzales; Jean L Patterson; Raymond P Goodrich
Journal:  Transfusion       Date:  2016-03       Impact factor: 3.157

2.  The Effects of Ultraviolet Light and Riboflavin on Inactivation of Viruses and the Quality of Platelet Concentrates at Laboratory Scale.

Authors:  Hamideh Mirshafiee; Zohreh Sharifi; Syed Masoud Hosseini; Fatemeh Yari; Hamed Nikbakht; Hamid Latifi
Journal:  Avicenna J Med Biotechnol       Date:  2015 Apr-Jun

Review 3.  Contemporary resuscitation of hemorrhagic shock: What will the future hold?

Authors:  Amanda M Chipman; Carleigh Jenne; Feng Wu; Rosemary A Kozar
Journal:  Am J Surg       Date:  2020-05-11       Impact factor: 2.565

4.  Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment.

Authors:  Shawn D Keil; Richard Bowen; Susanne Marschner
Journal:  Transfusion       Date:  2016-11-02       Impact factor: 3.157

Review 5.  Pathogen Reduction for Platelets-A Review of Recent Implementation Strategies.

Authors:  Paolo Rebulla; Daniele Prati
Journal:  Pathogens       Date:  2022-01-24

Review 6.  Riboflavin as a promising antimicrobial agent? A multi-perspective review.

Authors:  Nuratiqah Farah; Voon Kin Chin; Pei Pei Chong; Wai Feng Lim; Chee Woei Lim; Rusliza Basir; Sui Kiat Chang; Tze Yan Lee
Journal:  Curr Res Microb Sci       Date:  2022-02-10

7.  Robust inactivation of Plasmodium falciparum in red blood cell concentrates using amustaline and glutathione pathogen reduction.

Authors:  Cissé Sow; Amélie Bouissou; Yvette A Girard; Gurvani B Singh; Lotfi Bounaadja; Jean-Marc Payrat; Delphine Haas; Hervé Isola; Marion C Lanteri; Peter Bringmann; Philippe Grellier
Journal:  Transfusion       Date:  2022-04-06       Impact factor: 3.337

8.  Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination.

Authors:  Shawn D Keil; Nick Hovenga; Denise Gilmour; Susanne Marschner; Raymond Goodrich
Journal:  J Vis Exp       Date:  2015-08-24       Impact factor: 1.355

9.  Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment.

Authors:  Shawn D Keil; Izabela Ragan; Susan Yonemura; Lindsay Hartson; Nicole K Dart; Richard Bowen
Journal:  Vox Sang       Date:  2020-05-14       Impact factor: 2.996

10. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2022-04       Impact factor: 1.513

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.